News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChemoCentryx, Inc. (CCXI) Advances a New Generation CCR9 Inhibitor, CCX507, Into Clinical Development


1/7/2013 9:48:18 AM

MOUNTAIN VIEW, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today the initiation of a Phase I clinical trial for CCX507, the Company's novel, wholly-owned inhibitor of the chemokine receptor known as CCR9. The double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of CCX507 in healthy adult subjects.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES